The FDA approved several HDAC inhibitors for various hematological cancers; however, due to the low potency and undesirable safety profiles of these inhibitors, HDACIs that offer greater efficacy, safety, and tolerability need to be identified [20,21]. The gene discussed is HDAC9; the disease is hematopoietic and lymphoid cell neoplasm.